文献速递甲状腺疾病

多病共存背景下甲状腺功能与全因死亡率的关系:两项人群研究结果

Thyroid Function and All-cause Mortality in the Context of Multimorbidity: Results From 2 Population-based Studies.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

研究纳入PREVEND研究5537名(平均年龄53.0岁)和鹿特丹研究9080名(平均年龄64.9岁)参与者,按疾病状态分为无病、1种病和多病共存三组,采用Cox比例风险模型分析甲状腺功能与全因死亡率的关联。较高的游离T3浓度与1种病和多病共存组较低的死亡风险相关。

要点

  • 多病共存人群中,较高游离T4与全因死亡风险升高相关,且随疾病数量增加风险递增。
  • 较高游离T3与1种病和多病共存人群较低的死亡风险相关。
  • PREVEND研究中游离T4与死亡率的关联趋势相似但无统计学显著性。

核心结论

  • 在多病共存个体中,较高游离T4与全因死亡率升高相关,较低游离T3与较差的生存相关。
  • 研究结果将患者人群中的发现扩展至一般人群中的多病共存个体。

研究设计与样本

  • 基于PREVEND研究和鹿特丹研究的两项基于人群的队列研究。
  • 纳入有甲状腺功能测量和疾病状态记录的参与者,共5537名(PREVEND,平均年龄53.0岁)和9080名(鹿特丹研究,平均年龄64.9岁)。
  • 按疾病状态分为无病、1种病和多病共存三组,采用Cox比例风险模型分析甲状腺功能与全因死亡率的关联。

主要发现

  • PREVEND研究中游离T4与死亡率的关联趋势相似但无统计学显著性。

临床怎么用

  • 在多病共存患者中评估甲状腺功能时,较高的游离T4水平可能提示较高的全因死亡风险。
  • 较低的游离T3水平可能与多病共存患者较差的生存相关,需关注。

局限性

  • 研究结果是否适用于左甲状腺素使用者尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyroid dysfunction is common in aging populations and associated with increased noncommunicable disease risk. Complex disease interactions in multimorbidity may influence this association. We aimed to examine the association between thyroid function and all-cause mortality in the context of multimorbidity. METHODS: We included participants with thyroid function measurements and recorded disease status from the PREVEND and the Rotterdam studies and categorized them into 3 groups (no disease, 1 disease, and multimorbidity). We used Cox proportional hazards models for the associations between thyroid function and all-cause mortality. Hazard ratios (HRs) were expressed per 1-unit increment in thyroid function Z-scores. RESULTS: A total of 5537 participants (mean age, 53.0 years) from PREVEND and 9080 participants (mean age, 64.9 years) from the Rotterdam Study were included. Higher free T4 concentrations were associated with a higher all-cause mortality risk in the Rotterdam Study, with HRs per 1-unit increase in a Z-score of 1.07 (1.03-1.12), 1.09 (1.04-1.15), 1.21 (1.11-1.31) for individuals with no disease, 1 disease, and multimorbidity, respectively (P for trend <.001), whereas a similar but nonsignificant trend was observed in PREVEND. We show a lower mortality risk for higher free T3 concentrations among individuals with 1 disease (HR per 1-unit increase in Z-score: 0.82, 0.70-0.97) and multimorbidity (HR, 0.80; 0.61-1.05) (P for trend = .002). CONCLUSION: We show an association between higher free T4 and mortality for individuals with multimorbidity, whereas lower free T3 was associated with poor survival in individuals with multimorbidity. Our results extend findings from patient populations to people with multimorbidity from the general population. Future research is needed to investigate whether these findings extend to levothyroxine users.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Xu Y, Licher S, Visser WE, et al. Thyroid Function and All-cause Mortality in the Context of Multimorbidity: Results From 2 Population-based Studies. J Clin Endocrinol Metab. 2026. PMID: 40709437. doi:10.1210/clinem/dgaf425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。